Viking Therapeutics, Inc.
NASDAQ:VKTXBiotechnology
+$0.32 today
- Market cap
- $3.34B
- Beta
- 0.68
- P/E (TTM)
- -7.5
- EPS (TTM)
- -$4.09
Volume 2.87M
Average 2.20M
VKTX EBITDA
Earnings before interest, taxes, depreciation, and amortization; a proxy for operating profit before non-cash and financing charges.
Viking Therapeutics, Inc.NASDAQ: VKTX
EBITDA · Q2 FY2026 · quarter ended Jun 2026
EBITDA remains negative
Q2 FY2026 EBITDA was -$127.87M, compared with -$65.43M a year earlier. Trailing-twelve-month EBITDA was -$534.34M.
Context
- EBITDA grew in size in 3 of the last 3 fiscal years.
- FY2025 was the largest annual figure in the 4 fiscal years shown.
What to watch
Whether EBITDA reaches the consensus estimate from 10 analysts of $0 (+100.0%) for the fiscal year ending Dec 2026, a step up from the -227.9% reported in FY2025.
Sources:Income Statement Analyst consensus estimates Text generated from reported figures; not investment advice.
- Latest quarterJun 2026
- -$127.87M+19.2% QoQ
- Last fiscal yearDec 2025
- -$359.15M-227.9% YoY
- LTMJun 2026
- -$534.34M-212.4% YoY
| Horizon | Past | Forecast | Difference |
|---|---|---|---|
| Quarter | -95.4% | +100.0% | +195.4 pp |
| 1 year | -227.9% | +100.0% | +327.9 pp |
| 3-year CAGR | — | — | — |
| 5-year CAGR | — | — | |
| 10-year CAGR | — | — |
Forecasts compare the consensus estimate with the latest reported period. Difference is forecast minus past, in percentage points.
EBITDA history
USD · from the income statement
- Latest · FY2025
- (359.15M) USD
- Year-over-year change
- -227.9%
| Period | Period end | EBITDA | YoY change |
|---|---|---|---|
| FY2025 | 2025-12-31 | (359.15M) | -227.9% |
| FY2024 | 2024-12-31 | (109.52M) | -28.1% |
| FY2023 | 2023-12-31 | (85.52M) | -24.8% |
| FY2022 | 2022-12-31 | (68.52M) | -25.3% |
| FY2021 | 2021-12-31 | (54.68M) | — |
EBITDA vs competitors
How VKTX compares with its peers on the latest reported figures
- VKTX's LTM Jun 2026 EBITDA of -$534.34M is the lowest of the 7 companies compared; the peer median is -$153.31M.
- Its year-over-year change of -212.4% is the lowest of 6, against a peer median of -9.5%.
| Company | Period | LTM | YoY | 3-year CAGR | % of revenue |
|---|---|---|---|---|---|
| LTM Mar 2026 | -$715K | +96.9% | — | 1.9% | |
SEPNSepterna, Inc. | LTM Sep 2026 | -$57.07M | +24.4% | — | 59.3% |
MBXMBX Biosciences, Inc. Common Stock | LTM Sep 2026 | -$148.59M | -85.2% | — | — |
KLRAKailera Therapeutics, Inc. | FY2025 | -$158.03M | — | — | — |
| LTM Jun 2026 | -$254.91M | -32.5% | — | 3579.7% | |
| LTM Jun 2026 | -$292.07M | -9.5% | — | 22.7% | |
| LTM Jun 2026 | -$534.34M | -212.4% | — | — | |
| Peer median (excluding VKTX) | -$153.31M | -9.5% | — | 41.0% | |
Competitors are the stored peer set for VKTX. Fiscal calendars differ, so each company's latest period is shown. Text is generated from reported figures; not investment advice.
Income Statement
Metric | FY2021 Dec 2021 | FY2022 Dec 2022 | FY2023 Dec 2023 | FY2024 Dec 2024 | FY2025 Dec 2025 |
|---|---|---|---|---|---|
| Revenue | 0 | 0 | 0 | 0 | 0 |
| Cost of Revenue | 0 | 0 | 0 | 0 | 431K |
| Gross Profit | 0 | 0 | 0 | 0 | (431K) |
| Gross Margin | — | — | — | — | — |
| Research & Development | 44.98M | 54.23M | 63.81M | 101.64M | 344.96M |
| Selling, General & Admin | 10.7M | 16.12M | 37.02M | 49.28M | 48.39M |
| Operating Expenses | 55.68M | 70.36M | 100.83M | 150.92M | 393.34M |
| Depreciation & Amortization | 296K | 291K | 292K | 346K | 431K |
| EBITDA | (54.68M) | (68.52M) | (85.52M) | (109.52M) | (359.15M) |
| EBITDA Margin | — | — | — | — | — |
| Operating Income | (55.68M) | (70.36M) | (100.83M) | (150.92M) | (393.34M) |
| Operating Margin | — | — | — | — | — |
| Interest Income | 703K | 1.59M | 15.02M | 40.94M | 33.7M |
| Interest Expense | 18K | 59K | 88K | 94K | 0 |
| Other Income / Expenses | 692K | 1.49M | 14.93M | 40.96M | 33.7M |
| Income Before Tax | (54.99M) | (68.87M) | (85.9M) | (109.96M) | (359.64M) |
| Pre-Tax Margin | — | — | — | — | — |
| Income Tax Expense | 0 | 0 | 0 | 0 | 0 |
| Net Income | (54.99M) | (68.87M) | (85.9M) | (109.96M) | (359.64M) |
| Net Margin | — | — | — | — | — |
| EPS (Basic) | (0.70) | (0.88) | (0.91) | (1.01) | (3.19) |
| EPS (Diluted) | (0.70) | (0.88) | (0.91) | (1.01) | (3.19) |
| Weighted Avg Shares | 77.2M | 76.83M | 94.35M | 109.04M | 112.67M |
| Weighted Avg Shares (Diluted) | 77.2M | 76.83M | 94.35M | 109.04M | 112.67M |
Viking Therapeutics, Inc.
NASDAQ:VKTX
Intrinsic Alpha fair value
Locked
Current Price
$26.17
Unlock the intrinsic value to see where the current price sits on the valuation runway.
Valuation runway
LockedGet the intrinsic value and margin of safety with a free account.
Continue the stock analysis
Jump to another research area for this company.